716 related articles for article (PubMed ID: 27329806)
1. Understanding the mechanisms of faecal microbiota transplantation.
Khoruts A; Sadowsky MJ
Nat Rev Gastroenterol Hepatol; 2016 Sep; 13(9):508-16. PubMed ID: 27329806
[TBL] [Abstract][Full Text] [Related]
2. The role of the gut microbiome in colonization resistance and recurrent
Seekatz AM; Safdar N; Khanna S
Therap Adv Gastroenterol; 2022; 15():17562848221134396. PubMed ID: 36425405
[TBL] [Abstract][Full Text] [Related]
3. Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent
Mullish BH; McDonald JAK; Pechlivanis A; Allegretti JR; Kao D; Barker GF; Kapila D; Petrof EO; Joyce SA; Gahan CGM; Glegola-Madejska I; Williams HRT; Holmes E; Clarke TB; Thursz MR; Marchesi JR
Gut; 2019 Oct; 68(10):1791-1800. PubMed ID: 30816855
[TBL] [Abstract][Full Text] [Related]
4. Fecal Microbiota Transplantation Increases Colonic IL-25 and Dampens Tissue Inflammation in Patients with Recurrent Clostridioides difficile.
Jan N; Hays RA; Oakland DN; Kumar P; Ramakrishnan G; Behm BW; Petri WA; Marie C
mSphere; 2021 Oct; 6(5):e0066921. PubMed ID: 34704776
[TBL] [Abstract][Full Text] [Related]
5. Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease.
Khanna S; Vazquez-Baeza Y; González A; Weiss S; Schmidt B; Muñiz-Pedrogo DA; Rainey JF; Kammer P; Nelson H; Sadowsky M; Khoruts A; Farrugia SL; Knight R; Pardi DS; Kashyap PC
Microbiome; 2017 May; 5(1):55. PubMed ID: 28506317
[TBL] [Abstract][Full Text] [Related]
6. Restoration of short chain fatty acid and bile acid metabolism following fecal microbiota transplantation in patients with recurrent Clostridium difficile infection.
Seekatz AM; Theriot CM; Rao K; Chang YM; Freeman AE; Kao JY; Young VB
Anaerobe; 2018 Oct; 53():64-73. PubMed ID: 29654837
[TBL] [Abstract][Full Text] [Related]
7. Changes in microbiota composition, bile and fatty acid metabolism, in successful faecal microbiota transplantation for Clostridioides difficile infection.
Brown JR; Flemer B; Joyce SA; Zulquernain A; Sheehan D; Shanahan F; O'Toole PW
BMC Gastroenterol; 2018 Aug; 18(1):131. PubMed ID: 30153805
[TBL] [Abstract][Full Text] [Related]
8. Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent
Martinez-Gili L; McDonald JAK; Liu Z; Kao D; Allegretti JR; Monaghan TM; Barker GF; Miguéns Blanco J; Williams HRT; Holmes E; Thursz MR; Marchesi JR; Mullish BH
Gut Microbes; 2020 Nov; 12(1):1810531. PubMed ID: 32893721
[TBL] [Abstract][Full Text] [Related]
9. Functional profile of host microbiome indicates
Nzabarushimana E; Tang H
Gut Microbes; 2022; 14(1):2135963. PubMed ID: 36289064
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal Bile Acid Composition Changes Following Faecal Microbiota Transplantation for Clostridioides difficile Infection in Children With and Without Underlying Inflammatory Bowel Disease.
Chen LA; Oliva-Hemker M; Radin A; Weidner M; O'Laughlin BD; Sears CL; Javitt NB; Hourigan SK
J Crohns Colitis; 2023 Aug; 17(8):1364-1368. PubMed ID: 36988432
[TBL] [Abstract][Full Text] [Related]
11. Effective fecal microbiota transplantation for recurrent Clostridioides difficile infection in humans is associated with increased signalling in the bile acid-farnesoid X receptor-fibroblast growth factor pathway.
Monaghan T; Mullish BH; Patterson J; Wong GK; Marchesi JR; Xu H; Jilani T; Kao D
Gut Microbes; 2019; 10(2):142-148. PubMed ID: 30183484
[TBL] [Abstract][Full Text] [Related]
12. Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology.
Khoruts A; Staley C; Sadowsky MJ
Nat Rev Gastroenterol Hepatol; 2021 Jan; 18(1):67-80. PubMed ID: 32843743
[TBL] [Abstract][Full Text] [Related]
13. Faecal microbiota transplantation in the treatment of recurrent intestinal Clostridioides difficile infection - a ten-year single-center experience.
Pipek B; Valentová H; Fojtík P; Urban O
Cas Lek Cesk; 2022; 161(3-4):126-130. PubMed ID: 36100450
[TBL] [Abstract][Full Text] [Related]
14. Alteration of gut microbial composition associated with the therapeutic efficacy of fecal microbiota transplantation in Clostridium difficile infection.
Lee PC; Chang TE; Wang YP; Lee KC; Lin YT; Chiou JJ; Huang CW; Yang UC; Li FY; Huang HC; Wu CY; Huang YH; Hou MC
J Formos Med Assoc; 2022 Sep; 121(9):1636-1646. PubMed ID: 34836663
[TBL] [Abstract][Full Text] [Related]
15. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection.
Weingarden AR; Chen C; Bobr A; Yao D; Lu Y; Nelson VM; Sadowsky MJ; Khoruts A
Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G310-9. PubMed ID: 24284963
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting Growth of Clostridioides difficile by Restoring Valerate, Produced by the Intestinal Microbiota.
McDonald JAK; Mullish BH; Pechlivanis A; Liu Z; Brignardello J; Kao D; Holmes E; Li JV; Clarke TB; Thursz MR; Marchesi JR
Gastroenterology; 2018 Nov; 155(5):1495-1507.e15. PubMed ID: 30025704
[TBL] [Abstract][Full Text] [Related]
17. Fecal Microbiota Transplantation and Microbial Therapeutics for the Treatment of Clostridioides difficile Infection in Pediatric Patients.
Bernard R; Hourigan SK; Nicholson MR
J Pediatric Infect Dis Soc; 2021 Nov; 10(Supplement_3):S58-S63. PubMed ID: 34791396
[TBL] [Abstract][Full Text] [Related]
18. Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection Prevention.
Lavoie T; Appaneal HJ; LaPlante KL
Clin Infect Dis; 2023 Dec; 77(Suppl 6):S447-S454. PubMed ID: 38051964
[TBL] [Abstract][Full Text] [Related]
19. Successful therapy of Clostridium difficile infection with fecal microbiota transplantation.
Konturek PC; Koziel J; Dieterich W; Haziri D; Wirtz S; Glowczyk I; Konturek K; Neurath MF; Zopf Y
J Physiol Pharmacol; 2016 Dec; 67(6):859-866. PubMed ID: 28195066
[TBL] [Abstract][Full Text] [Related]
20. Improving Risk-Benefit in Faecal Transplantation through Microbiome Screening.
Papanicolas LE; Gordon DL; Wesselingh SL; Rogers GB
Trends Microbiol; 2020 May; 28(5):331-339. PubMed ID: 31952909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
